PaperTrue

     恭喜清华大学电子工程系余佳东团队喜中ADVANCED MATERIALS(IF:25.8),购买服务为:优质润色 点击查看更多发表案例
以下是对 LUNG CANCER 杂志介绍 收藏
缩写名/全名
LUNG CANCER
LUNG CANCER
ISSN号 0169-5002
研究方向 医学-呼吸系统
影响因子 2015:3.767, 2016:4.294, 2017:4.486, 2018:4.599, 2019:4.702,
出版国家 NETHERLANDS
出版周期 Monthly
年文章数 295
出版年份 1985
是否OA No
审稿周期(仅供参考) 一般,3-6周
来源Elsevier官网:平均5.9周
录用比例 较难
投稿链接 http://ees.elsevier.com/lungcancer/default.asp?pg=preRegistration.asp
投稿官网 http://www.journals.elsevier.com/lung-cancer/
h-index 114
CiteScore
CiteScoreSJRSNIPCiteScore排名
7.201.7051.288
学科分区排名
大类:Medicine
小类:Oncology
Q160 / 331
大类:Medicine
小类:Pulmonary and Respiratory Medicine
Q113 / 131
大类:Medicine
小类:Cancer Research
Q252 / 198

PubMed Central (PMC)链接 http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0169-5002%5BISSN%5D
中科院SCI期刊分区
( 2018年新版本)
大类学科小类学科Top期刊综述期刊
医学 2区2区2区
ONCOLOGY
肿瘤学
4区1区3区
RESPIRATORY SYSTEM
呼吸系统
2区1区2区
中科院SCI期刊分区
( 2020年新版本)
大类学科小类学科Top期刊综述期刊
医学 1区2区1区
ONCOLOGY
肿瘤学
2区1区2区
RESPIRATORY SYSTEM
呼吸系统
4区3区2区
  • 该杂志上中国学者近期发表的论文
  • 同领域相关期刊
中国学者近期发表的论文
1.Radiomics signature: A potential and incremental predictor for EGFR mutation status in NSCLC patients, comparison with CT morphology

Author: Wenting Tu, Guangyuan Sun, Li Fan, Yun Wang, Yi Xia, Yu Guan, Qiong Li, Di Zhang, Shiyuan Liu, Zhaobin Li
Journal: LUNG CANCER, 2019, Vol., , DOI:10.1016/j.lungcan.2019.03.025
    DOI
2.A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases

Author: Kai Yin, Yang-Si Li, Mei-Mei Zheng, Ben-Yuan Jiang, Wen-Feng Li, Jin-Ji Yang, Hai-Yan Tu, Qing Zhou, Wen-Zhao Zhong, Xue-Ning Yang, Hua-Jun Chen, Hong-Hong Yan, Lin-Lin Li, Yi-Long Wu, Xu-Chao Zhang
Journal: LUNG CANCER, 2019, Vol., , DOI:10.1016/j.lungcan.2019.03.015
    DOI
3.Is Spread Through Air Spaces should be considered as a staging profile in future staging system?

Author: Song Tieniu, Yidan Lin
Journal: LUNG CANCER, 2019, Vol., , DOI:10.1016/j.lungcan.2019.02.016
    DOI
4.Mutation tracking of a patient with EGFR-mutant lung cancer harboring de novo MET amplification: Successful treatment with gefitinib and crizotinib

Author: Xuanxuan Zheng, Guowei Zhang, Peng Li, Mina Zhang, Xiangtao Yan, Xiaojuan Zhang, Jinbo Yang, Haixia Li, Xiyang Liu, Zhiyong Ma, Huijuan Wang
Journal: LUNG CANCER, 2019, Vol.129, 72-74, DOI:10.1016/j.lungcan.2019.01.009
    DOI
5.Diagnosing a solitary pulmonary nodule using multiple bronchoscopic guided technologies: A prospective randomized study

Author: Liyan Bo, Congcong Li, Lei Pan, Hongwu Wang, Shiyue Li, Qiang Li, Chong Bai, Yiming Zeng, Yandong Nan, Yan Wang, Haidong Huang, Rui Zhou, Hongmei Zhou, Wen Liu, Jiayuan Sun, Zhiguang Liu, Faguang Jin
Journal: LUNG CANCER, 2019, Vol.129, 48-54, DOI:10.1016/j.lungcan.2019.01.006
    DOI
6.Identification of a novel WNK1–ROS1 fusion in a lung adenocarcinoma sensitive to crizotinib

Author: Yutao Liu, Tianfeng Liu, Nan Li, Tao Wang, Pu Yue, Rui Lin
Journal: LUNG CANCER, 2018, Vol., , DOI:10.1016/j.lungcan.2018.12.011
    DOI
7.Case report: Crizotinib is effective in a patient with ROS1-rearranged pulmonary inflammatory myofibroblastic tumor

Author: Shijie Mai, Gang Xiong, Dingwei Diao, Wenjing Wang, Yujie Zhou, Ruijun Cai
Journal: LUNG CANCER, 2018, Vol.128, 101-104, DOI:10.1016/j.lungcan.2018.12.016
    DOI
8.Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M

Author: Sha Zhao, Xuefei Li, Chao Zhao, Tao Jiang, Yijun Jia, Jinpeng Shi, Yayi He, Jiayu Li, Fei Zhou, Guanghui Gao, Wei Li, Xiaoxia Chen, Chunxia Su, Shengxiang Ren, Caicun Zhou
Journal: LUNG CANCER, 2018, Vol.128, 33-39, DOI:10.1016/j.lungcan.2018.12.010
    DOI
9.Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation

Author: Xiangtao Yan, Huijuan Wang, Peng Li, Guowei Zhang, Mina Zhang, Jinpo Yang, Xiaojuan Zhang, Xuanxuan Zheng, Zhiyong Ma
Journal: LUNG CANCER, 2018, Vol.128, 6-12, DOI:10.1016/j.lungcan.2018.12.007
    DOI
10.Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China

Author: Xiaohua Gu, Qiang Zhang, Yun-Bo Chu, Yi-Yang Zhao, Yan-Jun Zhang, David Kuo, Betty Su, Bin Wu
Journal: LUNG CANCER, 2018, Vol.127, 84-89, DOI:10.1016/j.lungcan.2018.11.029
    DOI
同类著名期刊名称 h-index CiteScore
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE34321.60
Journal of Thoracic Oncology11314.10
EUROPEAN RESPIRATORY JOURNAL21612.90
THORAX20013.30
CHEST26712.10
JOURNAL OF HEART AND LUNG TRANSPLANTATION12212.80
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY1478.10
RESPIROLOGY729.10
Journal of Cystic Fibrosis656.60
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY1807.10
中科院JCR同大类学科的热搜期刊 浏览次数
MEDICINE301730
CANCER RESEARCH166488
Molecular Medicine Reports165328
International Journal of Nanomedicine164993
CANCER LETTERS160133
JOURNAL OF ETHNOPHARMACOLOGY142388
BIOMEDICINE & PHARMACOTHERAPY141616
Theranostics136651
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY136512
International Journal of Environmental Research and Public Health134193